Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Dry Eye Syndromes: full-pipeline trial registry
1 of 19 indexed Dry Eye Syndromes trials are currently recruiting.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 1 currently recruiting · #902 of 28,707 conditions by registered trial count
Dry Eye Syndromes: 19 US clinical trials tracked, 1 recruiting.
Dry Eye Syndromes is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Allergan, running 3 of these trials.
Enrollment posture brief
Registry condition dry-eye-syndromes
OPEN 1 | RECR 5% | LATE 5 | EARLY 6 | RANK #902 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Recurrent Breast Cancer (5% recruiting · 20 trials)
Dry Eye Syndromes lists 1 open slots (5% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Dry Eye Syndromes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Dry Eye Syndromes is recruiting below its size-band peers.
1 of 19 indexed trials (5.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Dry Eye Syndromes research.
Allergan accounts for 3 of 19 trials (15.8%). 16 distinct sponsors appear on at least one study for this condition label.
-
Typical Dry Eye Syndromes enrolment sits around 130 participants.
Median target enrolment is 130 among the 18 trials that report a genuine target (sentinel values excluded). 8 of those (44.4%) plan for fewer than 100 participants.
-
Dry Eye Syndromes research is mostly interventional.
17 interventional and 2 observational studies make up this index (89.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
Clinical Applications of Advanced Ophthalmic Imaging
University of Miami
NCT03135327
Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals
Western University of Health Sciences
NCT05763940
Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease
Allergan
NCT01459588
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.
Seikagaku Corporation
NCT02205840
Diagnostic Evaluation of the Tear Film
TearScience
NCT00761917
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye
Kubota Vision
NCT01027013
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
Novaliq
NCT02617667
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
Allergan
NCT02910713
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye
Seikagaku Corporation
NCT01558999
TearLab Refractive Surgery Dry Eye Study
TearLab Corporation
NCT01176045
TrueTear in Sjogren's Disease Patients
University of Pennsylvania
NCT03719885
Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®
Allergan
NCT02554981
Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD
Lumenis Be
NCT02621593
ACCURATE Study for Subjects With Dry Eyes
The Eye Centers of Racine and Kenosha
NCT04237012
Dry Eye Assessment and Management: Feasibility Study
Asbell, Penny, M.D.
NCT01102257
Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease
Eye Surgeons of Indiana
NCT04413279
Corneal Epithelial Stem Cells and Dry Eye Disease
Sloan W. Rush, MD
NCT03302273
Topical Naloxone to Diagnose Ocular Pain
Seema Capoor
NCT04454281
Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)
Sirion Therapeutics
NCT00502073
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 2 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Dry Eye Syndromes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Dry Eye Syndromes trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Dry Eye Syndromes page
19 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Dry Eye Syndromes trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Allergan sponsors the most Dry Eye Syndromes trials on record, review their full trial history before evaluating a specific study. See Allergan's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dry Eye Syndromes condition card totals 19 registered trials; most-linked intervention Vehicle; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.